Monopar Therapeutics Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
0.00 |
0.00 |
0.76 |
15.14 |
57.05 |
125.45 |
| Przychód Δ r/r |
0.00% |
0.00% |
inf% |
1892.73% |
276.71% |
119.89% |
| Przychód (min) |
0.00 |
0.00 |
0.76 |
15.14 |
57.05 |
125.45 |
| Przychód (max) |
0.00 |
0.00 |
0.76 |
15.14 |
57.05 |
125.45 |
| EBITDA (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT % |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Zysk netto (średni) |
-5.22 |
-7.43 |
-12.96 |
-24.66 |
-6.87 |
7.01 |
| Zysk netto % |
-inf% |
-inf% |
-1704.91% |
-162.82% |
-12.04% |
5.59% |
| EPS (średnia) |
-1.38 |
-1.96 |
-3.29 |
-3.42 |
-1.81 |
1.85 |
| Liczba analityków (Przychody) |
0 |
0 |
7 |
6 |
2 |
5 |
| Liczba analityków (EPS) |
3 |
4 |
5 |
5 |
2 |
1 |
| symbol |
MNPR |
MNPR |
MNPR |
MNPR |
MNPR |
MNPR |